Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM)
J. Clin. Oncol., Jun 03 2024, | https://doi.org/10.1200/JCO.24.00708
A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)
J. Clin. Oncol., Oct 20 2023, | https://doi.org/10.1200/JCO.23.01891
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment
J. Immunother. Cancer, 2023 Feb;11(2):e005509 | http://dx.doi.org/10.1136/jitc-2022-005509
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
J. Clin. Oncol., Published online March 10, 2022 | DOI: 10.1200/JCO.21.02010